Roche
Roche’s Zelboraf rejected by NICE
June 15, 2012Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma
NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …
FDA approves Roche’s breast cancer drug
June 11, 2012Sales and Marketing EMA, FDA, Perjeta, Roche, breast cancer
US regulators have approved Roche’s new breast cancer drug after granting it a priority review to speed up the process. …
Herceptin successor impresses at ASCO
June 6, 2012Research and Development, Sales and Marketing ASCO, Cancer, EMILIA, FDA, Roche, T-DM1
Roche’s new ‘smart bomb’ breast cancer drug T-DM1 has impressed at this year’s ASCO conference in Chicago. The trial showed it …
GSK starts combination trial for melanoma
May 30, 2012Research and Development, Sales and Marketing GSK, R&D, Roche, Zelboraf, melanoma
GlaxoSmithKline has begun a combination trial for two of its investigational skin cancer drugs. The firm will combine dabrafenib, its …
EMA backs MabThera despite contamination issue
May 29, 2012Manufacturing and Production EMA, MabThera, Phil Taylor, Roche, manufacturing
The European Medicines Agency has completed a safety review of Roche’s MabThera convened after bacterial contamination was discovered in bioreactors …
Discount sways NICE into recommending Tarceva
May 10, 2012Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer
NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease. The watchdog said …
Roche abandons Phase III cholesterol drug
May 8, 2012Medical Communications, Research and Development, Sales and Marketing CETP inhibitor, Roche, cardiovascular, dalcetrapib, phase III failure
Roche has abandoned its Phase III cholesterol treatment dalcetrapib after disappointing results.The manufacturer is ceasing work on the drug, once …
Roche and Novartis have best websites
May 3, 2012Medical Communications Bowen Craggs & Co, Novartis, Pfizer, Roche, Shell, digital, web
A new survey of leading international companies has found Roche and Novartis have the best websites in the pharma sector. …
GMC won’t relax off-label prescribing guidelines
April 25, 2012Sales and Marketing GMC, Lucentis, Novartis, Roche, avastin, off label, off-label
The GMC has decided not to relax guidelines on off-label prescribing when a licensed alternative exists. The GMC’s current rules …
New data shows Herceptin’s ability to increase survival
April 24, 2012Research and Development, Sales and Marketing Cancer, Cochrane, Herceptin, Roche, breast
A new review of Roche’s breast cancer drug Herceptin has confirmed its ability to increase overall survival, but concerns remain …
Charity challenges government on Avastin for wet AMD
April 24, 2012Sales and Marketing Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD
A leading patient group has called on the government to get to grips with the issue of off-label prescribing, as …
Government to speed up access to new cancer drugs
April 24, 2012Sales and Marketing CDF, Cancer, Roche, UK, avastin, government, sha
Access to England’s Cancer Drugs Fund will be speeded up, ministers have confirmed. Currently, it can take a number of …
Kantar Health appoints Richard Goosey as UK senior director
April 20, 2012Business Services, Medical Communications, Sales and Marketing Kantar Health, Richard Goosey, Roche
Consultancy and marketing insights company Kantar Health has appointed Richard Goosey as UK senior director of Advanced Methods. Goosey has …
Roche abandons Illumina takeover bid
April 19, 2012Sales and Marketing Diagnostics, Illumina, Roche, mergers and acquisitions
Roche has conceded defeat in its bid to buy Illumina, after shareholders of the diagnostics firm blocked the takeover – …
NICE rejects Avastin for breast cancer
April 18, 2012Sales and Marketing EMA, NICE, Roche, avastin, breast cancer
In a blow for Roche, NICE has turned down its cancer drug Avastin because of ‘too many uncertainties’ over cost …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
